BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
BioLife Solutions Chief Financial Officer Troy Wichterman reported a routine tax-related share disposition. On the reported date, 1,026 shares of common stock were withheld by the company to satisfy his tax withholding obligations arising from the release of restricted stock units, rather than being sold in the open market.
After this tax-withholding event, Wichterman directly holds 215,030 shares of BioLife Solutions common stock, indicating he retains a substantial equity position. This filing reflects a compensation-related, non-discretionary transaction tied to vesting, not an active decision to buy or sell shares on the market.
BioLife Solutions Inc. Chief Marketing Officer Todd Berard reported a routine tax-related share disposition. On the release of restricted stock units, 356 shares of Common Stock were withheld by the company to cover his tax withholding obligations. Following this, he directly holds 163,412 shares, so his overall stake remains largely unchanged and the transaction does not represent an open-market sale.
BIOLIFE SOLUTIONS INC executive Mathew Aby J., EVP & Chief Scientific Officer, reported a small, routine share disposition related to taxes. On June 8, 2026, 627 shares of common stock were withheld at $26.10 per share to satisfy tax withholding obligations that arose when restricted stock units were released. After this tax-withholding event, he directly held 389,540 shares of common stock.
BioLife Solutions Inc. ownership update: Casdin Capital, LLC and related entities report shared beneficial ownership of 4,757,165 shares of Common Stock, representing 9.7% of the class as reported on 06/04/2026. The reported shares are held by advisory clients, including Casdin Partners Master Fund, L.P., and the filing disclaims direct sole voting or dispositive power.
BioLife Solutions, Inc. furnished an investor presentation outlining its strategy and recent financial performance for cell-based therapy tools. The company reported pro forma 2025 revenue of $96.2M, up 29% from 2024, with a 65% gross margin and 26% adjusted EBITDA margin.
Q1 2026 revenue was $27.5M with adjusted EBITDA of $6.2M, a 22% margin. Management highlights leadership in biopreservation media, growing adoption across more than 950 active clinical trials and multiple approved therapies, and targets 17–20% revenue growth and positive GAAP net income for full-year 2026.
BioLife Solutions, Inc. investor Casdin Capital and affiliates report a 9.7% beneficial ownership stake, or 4,757,165 common shares. This percentage is based on 48,857,415 shares outstanding as of April 30, 2026. The stake is held through Casdin Partners Master Fund, L.P., its general partner, and Eli Casdin.
The shares were acquired for investment using the fund’s working capital, without specific borrowing for this position. The group states it currently has no concrete plans for corporate changes but may engage with management, directors, and other shareholders on alternatives to maximize shareholder value and could adjust its holdings over time.
BioLife Solutions Inc. reported insider activity by Casdin-affiliated entities. Casdin Partners Master Fund, L.P. completed open-market sales totaling 1,200,000 shares of common stock over three days. The fund sold 300,000 shares at $22.65 on May 19, 2026, 250,000 shares at $23.70 on May 20, and 650,000 shares at $23.70 on May 21. After these sales, the Master Fund continued to hold 4,757,165 shares indirectly. According to the footnote, these securities are owned directly by the Master Fund and may be deemed indirectly beneficially owned by Casdin Capital, LLC, Casdin Partners GP, LLC, and Eli Casdin.
BioLife Solutions Inc. reports that Casdin Partners Master Fund, L.P., a 10% shareholder, filed a notice of a proposed sale of 650,000 common shares, with an approximate sale date of May 21, 2026. The notice lists an aggregate market value of $15.6 million and names BMO Capital Markets as broker. The fund acquired 650,000 shares directly from the issuer for cash on August 13, 2018. It also lists the fund's sales of 300,000 shares for gross proceeds of $6,795,000 on May 19, 2026, and 250,000 shares for gross proceeds of $5,925,000 on May 20, 2026. Eli Casdin signed the notice.
BIOLIFE SOLUTIONS INC (BLFS) is named in a notice by its 10% shareholder, Casdin Partners Master Fund, L.P., proposing the sale of 250,000 common shares, with an aggregate market value of $6,000,000.00 and an approximate sale date of May 20, 2026. BMO Capital Markets is named as broker.
Casdin Partners Master Fund, L.P. also reported selling 300,000 shares on May 19, 2026, for gross proceeds of $6,795,000.00. The proposed-sale shares were acquired on August 13, 2018, in a purchase directly from the issuer for cash. Eli Casdin signed the notice.
BioLife Solutions submitted a Form 144 notice indicating proposed sale of 300,000 shares of Common Stock. The filing lists an aggregate value of $6,690,000.00 and references 48,857,415 shares outstanding as of 05/19/2026.
The shares were purchased from the issuer on 08/13/2018 for cash; the filing lists BMO Capital Markets as a broker-dealer. The filing is a notice of a planned sale under resale rules.